Hormone therapy before surgery for extensive DCIS
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 study tests whether taking hormone medicine before surgery can change the surgical plan and outcomes for people with extensive ductal carcinoma in situ (DCIS). It is for estrogen-receptor positive DCIS and aims to see how this “neoadjuvant” approach affects treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 40 years old
- Have DCIS (a non-invasive breast condition), not invasive cancer
- Your DCIS must be estrogen-receptor positive; progesterone status doesn’t matter
- Your planned surgery is a mastectomy (removal of the breast)
- Your DCIS must be seen on a breast MRI, and an MRI “clip sequence” is used
- You should be able to attend follow-up visits and complete the study; also able to use effective birth control if you can become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether hormone therapy can safely treat certain non-invasive breast conditions (like DCIS) instead of surgery. It may offer an option to avoid surgery if the condition is low-risk.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This trial tests whether taking hormone therapy for 3 months before breast-conserving surgery can help doctors decide if radiation is right for you. It is for women aged 65 and older with a common type of breast cancer that is hormone receptor-positive and HER2-negative.
This trial tests if giving hormone-blocking pills before surgery can help guide which treatments you need after surgery. It is for premenopausal women with early-stage, hormone-sensitive breast cancer.
This trial tests giving trastuzumab (a targeted drug) plus a chemotherapy drug called a taxane before surgery for women with HER2-positive ductal carcinoma in situ (DCIS), an early form of breast cancer. The goal is to see if this combination can shrink or eliminate the cancer before surgery.
This trial tests giving chemotherapy before surgery to shrink breast tumors, which may make surgery easier or allow breast-conserving options. It is for adults with invasive breast cancer that has not spread to distant organs.
Hear when a new Ductal Carcinoma in Situ trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.